Pancreatitis - chronic
Exam Tips
- In chronic pancreatitis, serum amylase can be normal; do not exclude diagnosis on a normal amylase alone.
- Pancreatic ductal calcification on imaging is classically pathognomonic and strongly exam-relevant.
- Think type 3c diabetes (pancreatic diabetes) rather than type 2 when chronic pancreatitis coexists with malabsorption and weight loss.
- Steatorrhoea usually indicates substantial exocrine failure and should prompt PERT titration plus fat-soluble vitamin assessment.
- Persistent pain despite optimized medical therapy plus a dilated obstructed duct suggests endoscopic/surgical decompression consideration.
- Image revision point: review a textbook figure showing pancreatic fibrosis, ductal dilatation/calcification, and pseudocyst anatomy (e. g, core surgery/gastro text imaging chapter).
Definition
Chronic pancreatitis is a long-standing, irreversible fibro-inflammatory disorder of the pancreas, usually evolving from recurrent pancreatic injury and inflammation. It causes progressive structural damage (including ductal distortion and calcification) with loss of exocrine and endocrine function, leading to maldigestion, malabsorption, and pancreatogenic (type 3c) diabetes.
Pathophysiology
Repeated pancreatic inflammation (commonly alcohol-related, but also genetic, obstructive, autoimmune, metabolic, and toxic causes) drives acinar cell injury, stellate-cell activation, and collagen deposition, producing fibrosis and ductal stricturing/calcification. Ductal obstruction and intrapancreatic hypertension contribute to ischemia and ongoing inflammation; neural remodeling plus peripheral/central sensitization explains severe chronic pain. Exocrine tissue loss reduces lipase/protease/bicarbonate secretion, causing steatorrhoea and micronutrient deficiency, while islet damage causes insulin (and other hormone) deficiency with brittle glycaemia and high hypoglycaemia risk in type 3c diabetes.
Risk Factors
- Alcohol misuse (major cause; around 70-80% of cases in many cohorts)
- Smoking (earlier onset and faster progression, especially with alcohol)
- Recurrent acute pancreatitis (strong predictor of progression to chronic disease)
- Hypertriglyceridaemia
- Hypercalcaemia
- Autoimmune pancreatitis
- Genetic variants/family history (especially onset before age 35 years)
- Obstructive pancreatic disease (duct stricture/stones, tumour, gallstone-related obstruction)
- Drug exposure (for example thiazides, azathioprine, tetracyclines, oestrogens, valproate, cimetidine, DPP-4 inhibitors)
- Idiopathic disease (no clear cause found)
Clinical Features
Symptoms
- Persistent or recurrent deep epigastric pain, often radiating to the back
- Pain worse after meals, sometimes eased by sitting forward
- Nausea and vomiting
- Steatorrhoea (oily, foul-smelling, difficult-to-flush stool)
- Bloating, diarrhoea, abdominal cramps, excessive flatus
- Weight loss and reduced oral intake
- Symptoms of hyperglycaemia or pancreatogenic diabetes
- Pain may be absent in a minority despite advanced disease
Signs
- Epigastric tenderness
- Low BMI and clinical malnutrition (muscle wasting, vitamin deficiency features)
- Jaundice (biliary obstruction, liver disease, or pancreatic head pathology)
- Abdominal distension/mass (pseudocyst, ascites, or malignancy)
- Signs of chronic liver disease in alcohol-related cases
Investigations
Management
Lifestyle Modifications
- Absolute alcohol abstinence with formal alcohol-dependence support where needed
- Smoking cessation (brief intervention plus pharmacotherapy/stop-smoking services)
- Dietetic input: high-calorie, high-protein intake in malnourished patients; small frequent meals
- Monitor and replace deficiencies (A, D, E, K, B12, folate, iron, zinc, selenium, magnesium)
- Bone protection strategy (DEXA assessment where indicated, vitamin D/calcium optimisation, fracture prevention)
- Vaccination and sick-day education if diabetes or postsurgical endocrine failure develops
Pharmacological Treatment
Pancreatic enzyme replacement therapy (PERT)
- Pancreatin gastro-resistant capsules (e. g, Creon) typically 25000-50000 units lipase with main meals and 10000-25000 units with snacks, titrated to stool/weight response
Take with all meals/snacks; increase dose stepwise if steatorrhoea persists. Consider adding a proton pump inhibitor to improve efficacy. Do not crush/chew capsules (oral mucosal irritation); very high chronic doses have been linked to fibrosing colonopathy (especially in cystic fibrosis).
Acid suppression adjunct
- Omeprazole 20 mg once daily, increased to 40 mg once daily if needed
- Lansoprazole 15-30 mg once daily
Useful when suboptimal response to PERT due to acid-mediated enzyme inactivation. Review long-term PPI need (fracture risk, hypomagnesaemia, C. difficile risk).
Analgesia (stepwise, multimodal)
- Paracetamol 1 g up to four times daily (maximum 4 g/day)
- Ibuprofen 400 mg three times daily with food if no contraindication
- Codeine phosphate 30-60 mg every 4-6 hours when required (maximum 240 mg/day)
- Morphine sulfate oral immediate-release 5-10 mg every 4 hours when required for severe pain (specialist review)
Use WHO-style escalation with regular review. Avoid/limit NSAIDs in CKD, heart failure, peptic ulcer disease, anticoagulation, or high GI-risk states. In liver disease/alcohol misuse, ensure safe paracetamol dosing. Opioids carry dependence, constipation, endocrine suppression, and overdose risk; involve pain/gastro specialists early.
Neuropathic pain adjuncts (selected patients)
- Amitriptyline 10 mg at night, titrating gradually (commonly to 25-75 mg at night)
- Pregabalin 75 mg twice daily, titrating to response (usual range 150-600 mg/day)
Consider when neuropathic features or central sensitization are suspected. Amitriptyline is cautioned in arrhythmia, glaucoma, and high anticholinergic burden; pregabalin may cause sedation, dizziness, edema, and dependence risk.
Glycaemic management in type 3c diabetes
- Insulin regimens (e. g, basal-bolus) individualized to capillary glucose/HbA1c
- Metformin 500 mg once daily with food, titrated gradually if insulin resistance coexists and renal function allows
Type 3c diabetes often progresses to insulin deficiency; hypoglycaemia risk is higher due to impaired glucagon response. Check renal function before metformin (avoid in severe renal impairment) and provide structured hypoglycaemia education.
Surgical / Interventional
- Endoscopic therapy (ERCP-guided duct stone extraction, stricture dilation/stenting) for obstructive painful disease
- Extracorporeal shock-wave lithotripsy for large pancreatic duct stones
- EUS-guided or surgical drainage of symptomatic/complicated pseudocysts
- Surgical drainage procedures (e. g, longitudinal pancreaticojejunostomy) for dilated duct disease
- Resection procedures (e. g, pancreatic head resection/Whipple or duodenum-preserving head resection) in selected refractory cases or suspected malignancy
- Total pancreatectomy with islet autotransplantation in highly selected specialist-centre patients
Complications
- Pancreatic exocrine insufficiency with steatorrhoea and malabsorption
- Protein-calorie malnutrition and micronutrient deficiencies
- Type 3c (pancreatogenic) diabetes mellitus with increased hypoglycaemia risk
- Chronic debilitating pain with opioid dependence risk
- Osteopenia/osteoporosis and fragility fractures
- Pancreatic duct calcification, stones, strictures, and fistulae
- Pseudocyst (with possible infection, bleeding, rupture, or compression)
- Pseudoaneurysm and haemorrhage
- Splenic or portal vein thrombosis with variceal bleeding risk
- Increased risk of pancreatic adenocarcinoma (higher still in hereditary forms)
Prognosis
Outcome is heterogeneous and depends on cause (especially ongoing alcohol/smoking exposure), comorbidity, and complication burden. Long-term studies show reduced survival compared with the general population (approximately 70% at 10 years and 45% at 20 years in historical cohorts), with progression from painful relapsing disease to dominant endocrine/exocrine failure over time. Early risk-factor modification and specialist multidisciplinary care improve symptom control and nutritional/metabolic outcomes.
Sources & References
✅NICE Guidelines(1)
- Pancreatitis - chronic[overview]
📖Textbook References(20)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 797)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 659)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 794)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1828)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 797)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 686, 687)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 825)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 825, 826)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 282)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 273)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1149, 1150)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1152)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1152)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1151)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1154)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1152)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1137, 1138)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1144, 1145)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 109)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 962, 963)[context]